EA200401515A1 - Новые фармацевтические композиции, содержащие флибансерин в полиморфной модификации а - Google Patents

Новые фармацевтические композиции, содержащие флибансерин в полиморфной модификации а

Info

Publication number
EA200401515A1
EA200401515A1 EA200401515A EA200401515A EA200401515A1 EA 200401515 A1 EA200401515 A1 EA 200401515A1 EA 200401515 A EA200401515 A EA 200401515A EA 200401515 A EA200401515 A EA 200401515A EA 200401515 A1 EA200401515 A1 EA 200401515A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical compositions
compositions containing
new pharmaceutical
polymorphic modification
containing flibanserin
Prior art date
Application number
EA200401515A
Other languages
English (en)
Other versions
EA007185B1 (ru
Inventor
Томас Фридль
Гуидо Бернхард Эдмунд Радтке
Original Assignee
Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг filed Critical Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг
Publication of EA200401515A1 publication Critical patent/EA200401515A1/ru
Publication of EA007185B1 publication Critical patent/EA007185B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

В заявке описаны фармацевтические композиции для перорального применения, содержащие флибансерин, способы их получения и их применение в качестве лекарственного средства.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200401515A 2002-05-22 2003-05-19 Новые фармацевтические композиции, содержащие флибансерин в полиморфной модификации а EA007185B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02011224 2002-05-22
PCT/EP2003/005226 WO2003097058A1 (en) 2002-05-22 2003-05-19 New pharmaceutical compositions containing flibanserin polymorph a

Publications (2)

Publication Number Publication Date
EA200401515A1 true EA200401515A1 (ru) 2005-06-30
EA007185B1 EA007185B1 (ru) 2006-08-25

Family

ID=29433081

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200401515A EA007185B1 (ru) 2002-05-22 2003-05-19 Новые фармацевтические композиции, содержащие флибансерин в полиморфной модификации а

Country Status (25)

Country Link
EP (1) EP1511489B1 (ru)
JP (1) JP3919788B2 (ru)
KR (1) KR101054237B1 (ru)
CN (3) CN1655789A (ru)
AT (1) ATE499939T1 (ru)
BR (1) BRPI0311189B8 (ru)
CA (1) CA2483597C (ru)
CY (1) CY1111470T1 (ru)
DE (1) DE60336225D1 (ru)
DK (1) DK1511489T3 (ru)
EA (1) EA007185B1 (ru)
EC (1) ECSP045493A (ru)
ES (1) ES2361994T3 (ru)
HR (1) HRP20041092B1 (ru)
IL (1) IL164440A0 (ru)
ME (1) MEP55308A (ru)
MX (1) MXPA04011487A (ru)
NO (1) NO329414B1 (ru)
NZ (1) NZ537253A (ru)
PL (1) PL211062B1 (ru)
RS (1) RS51718B (ru)
SI (1) SI1511489T1 (ru)
UA (1) UA80135C2 (ru)
WO (1) WO2003097058A1 (ru)
ZA (1) ZA200408151B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
CA2608713A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of sexual dysfunctions due to medical conditions
WO2006125042A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
JP2009503020A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
CA2626134C (en) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
DE602007004615D1 (de) * 2006-06-30 2010-03-18 Boehringer Ingelheim Pharma Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
BRPI0716439B8 (pt) 2006-08-14 2021-05-25 Boehringer Ingelheim Int sistemas de liberação farmacêutico compreendendo flibanserina, processo para preparação e uso dos mesmos
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
WO2008022932A2 (en) 2006-08-25 2008-02-28 Boehringer Ingelheim International Gmbh Controlled release system and method for manufacturing the same
WO2008074795A1 (en) 2006-12-20 2008-06-26 Boehringer Ingelheim International Gmbh Sulfated benzimidazolone derivatives having mixed serotonine receptor affinity
EP1955699A1 (en) * 2007-02-08 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Use of flibanserin for the treatment of insomnia
UY31335A1 (es) 2007-09-12 2009-04-30 Tratamiento de sintomas vasomotores
EP2090297A1 (en) * 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
CN104926734B (zh) * 2015-07-07 2017-04-05 苏州立新制药有限公司 氟班色林的制备方法
CN108699007A (zh) * 2016-01-31 2018-10-23 孟晓明 氟班色林的新晶型及其制备方法及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
PL210224B1 (pl) * 2001-08-02 2011-12-30 Bidachem Spa Krystaliczna odmiana polimorficzna flibanseryny, sposób jej wytwarzania, jej zastosowanie, oraz kompozycje farmaceutyczne ją zawierające
DE10138273A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Arzneimittel mit neuroprotektiver Wirkung

Also Published As

Publication number Publication date
CN101002780A (zh) 2007-07-25
DE60336225D1 (de) 2011-04-14
ZA200408151B (en) 2006-06-28
EA007185B1 (ru) 2006-08-25
HRP20041092A2 (en) 2005-06-30
ES2361994T3 (es) 2011-06-27
MXPA04011487A (es) 2005-02-14
PL211062B1 (pl) 2012-04-30
PL372457A1 (en) 2005-07-25
ECSP045493A (es) 2005-03-10
BR0311189A (pt) 2005-02-22
RS98704A (en) 2006-12-15
BRPI0311189B1 (pt) 2019-04-09
EP1511489A1 (en) 2005-03-09
EP1511489B1 (en) 2011-03-02
CA2483597A1 (en) 2003-11-27
WO2003097058A1 (en) 2003-11-27
ATE499939T1 (de) 2011-03-15
SI1511489T1 (sl) 2011-06-30
JP3919788B2 (ja) 2007-05-30
CY1111470T1 (el) 2015-08-05
UA80135C2 (en) 2007-08-27
NZ537253A (en) 2007-09-28
DK1511489T3 (da) 2011-05-02
KR20040111668A (ko) 2004-12-31
NO20044547L (no) 2004-12-17
JP2005530787A (ja) 2005-10-13
RS51718B (en) 2011-10-31
CN1655789A (zh) 2005-08-17
HRP20041092B1 (hr) 2013-05-31
AU2003240672A1 (en) 2003-12-02
NO329414B1 (no) 2010-10-18
KR101054237B1 (ko) 2011-08-08
CN102240289A (zh) 2011-11-16
MEP55308A (en) 2011-05-10
BRPI0311189B8 (pt) 2021-05-25
CA2483597C (en) 2010-02-09
IL164440A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
NO20063429L (no) Brusende oral opiat doseringsform
IL163831A0 (en) Derivatives of aminoindazoles, method of preparation and intermediates of the method as drugs pharmaceutical compounds containing
UA96449C2 (en) Stable laquinimod preparations
DK1592457T3 (da) Folat-vinblastin-konjugat som lægemiddel
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
SE0301653D0 (sv) Novel compounds
ITMI20031570A1 (it) Composizione per uso dietetico, farmaceutico o cosmetico
DE60317803D1 (de) Pharmazeutische zusammensetzungen enthaltend cyclosporin zur oralen verabreichung
NO20064808L (no) Orale matrixformuleringer med licarbazepin
DE60304599D1 (de) Pyridopyrimidinon-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
TW200509992A (en) Dosage form containing pantoprazole as active ingredient
MX260260B (es) Formulaciones semi-solidas para la administracion oral de taxoides.
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
UA87152C2 (ru) Твердая фармацевтическая композиция, содержащая миртазапин, и способ ее получения
TW200503783A (en) Oral pharmaceutical preparation for proton pump antagonists
AU2003284786A8 (en) Microemulsion composition for oral administration of biphenyldimethyldicarboxylate
MXPA05007253A (es) Sales novedosas de derivados anticonvulsivantes.
DE502004003170D1 (de) Schmelzformulierte, multipartikuläre orale darreichungsform enthaltend clavulansäure
ITTO20020672A1 (it) Composizioni farmaceutiche contenenti cheto-acidi per somministrazione endoperitoneale
EP1361866A4 (en) EMULSIONS AS SOLID DOSAGE FORMS FOR ORAL ADMINISTRATION
DE50306757D1 (de) Zubereitungen zur oralen Aufnahme
DK1399143T3 (da) Anvendelsen af Acetyl L-carnitin til fremstilling af et lægemiddel til behandling af anhedoni
TNSN06299A1 (en) Oral matrix formulations comprising licarbazepine
IL175282A0 (en) Preparation of pharmaceutical salts of [1,4]-bipiperidine

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU